SG187808A1 - Vesicle composition, and external skin preparation and cosmetic, each containing same - Google Patents
Vesicle composition, and external skin preparation and cosmetic, each containing same Download PDFInfo
- Publication number
- SG187808A1 SG187808A1 SG2013010277A SG2013010277A SG187808A1 SG 187808 A1 SG187808 A1 SG 187808A1 SG 2013010277 A SG2013010277 A SG 2013010277A SG 2013010277 A SG2013010277 A SG 2013010277A SG 187808 A1 SG187808 A1 SG 187808A1
- Authority
- SG
- Singapore
- Prior art keywords
- vesicle
- vesicle composition
- component
- acid
- examples
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000012528 membrane Substances 0.000 claims abstract description 19
- 125000002328 sterol group Chemical group 0.000 claims abstract description 18
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 10
- 239000000470 constituent Substances 0.000 claims abstract description 6
- 229930182558 Sterol Natural products 0.000 claims description 15
- 150000003432 sterols Chemical class 0.000 claims description 15
- 235000003702 sterols Nutrition 0.000 claims description 15
- 229940106189 ceramide Drugs 0.000 claims description 11
- 150000001783 ceramides Chemical class 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 36
- 239000003792 electrolyte Substances 0.000 description 26
- -1 phytosterol Substances 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 150000003904 phospholipids Chemical class 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 150000001298 alcohols Chemical class 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000002875 fluorescence polarization Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229940068065 phytosterols Drugs 0.000 description 9
- 229940107161 cholesterol Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 7
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 244000027321 Lychnis chalcedonica Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000000235 small-angle X-ray scattering Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 3
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 3
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 3
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 3
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 3
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 3
- 235000004420 brassicasterol Nutrition 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical class OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229940058690 lanosterol Drugs 0.000 description 3
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920000867 polyelectrolyte Polymers 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- GHIZCSMTYWOBQA-BZSCQJQFSA-N spinasterol Natural products CC[C@H](C=C[C@@H](C)[C@@H]1CC[C@@]2(C)C3=CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C GHIZCSMTYWOBQA-BZSCQJQFSA-N 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- IOWMKBFJCNLRTC-XWXSNNQWSA-N (24S)-24-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](O)C(C)C)[C@@]1(C)CC2 IOWMKBFJCNLRTC-XWXSNNQWSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OOWQBDFWEXAXPB-IBGZPJMESA-N 1-O-hexadecyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)CO OOWQBDFWEXAXPB-IBGZPJMESA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IOWMKBFJCNLRTC-UHFFFAOYSA-N 24S-hydroxycholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(O)C(C)C)C1(C)CC2 IOWMKBFJCNLRTC-UHFFFAOYSA-N 0.000 description 2
- NRWMBHYHFFGEEC-MDZDMXLPSA-N 3-[(e)-octadec-9-enoxy]propane-1,2-diol Chemical compound CCCCCCCC\C=C\CCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-MDZDMXLPSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- UJELMAYUQSGICC-UHFFFAOYSA-N Zymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)C=CCC(C)C)CCC21 UJELMAYUQSGICC-UHFFFAOYSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OOWQBDFWEXAXPB-UHFFFAOYSA-N chimyl alcohol Natural products CCCCCCCCCCCCCCCCOCC(O)CO OOWQBDFWEXAXPB-UHFFFAOYSA-N 0.000 description 2
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000005486 organic electrolyte Substances 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- NRWMBHYHFFGEEC-UHFFFAOYSA-N selachyl alcohol Natural products CCCCCCCCC=CCCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- CGSJXLIKVBJVRY-XTGBIJOFSA-N zymosterol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@H]21 CGSJXLIKVBJVRY-XTGBIJOFSA-N 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- RBMGJIZCEWRQES-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(N)=O RBMGJIZCEWRQES-DKWTVANSSA-N 0.000 description 1
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical class CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- JAUFWPNLLLUYNV-UHFFFAOYSA-N 3-(16-methylheptadecoxy)propane-1,2-diol Chemical compound CC(C)CCCCCCCCCCCCCCCOCC(O)CO JAUFWPNLLLUYNV-UHFFFAOYSA-N 0.000 description 1
- UBHINGQGGSTHQT-UHFFFAOYSA-N 3-(8-methylnonoxy)propane-1,2-diol Chemical compound CC(C)CCCCCCCOCC(O)CO UBHINGQGGSTHQT-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- BUADUHVXMFJVLH-UHFFFAOYSA-N 7-chloro-3-imidazol-1-yl-2H-1,2,4-benzotriazin-1-ium 1-oxide Chemical compound N1[N+](=O)C2=CC(Cl)=CC=C2N=C1N1C=CN=C1 BUADUHVXMFJVLH-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 239000005714 Chitosan hydrochloride Substances 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102100031613 Hypermethylated in cancer 2 protein Human genes 0.000 description 1
- 101710091638 Hypermethylated in cancer 2 protein Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 150000001201 N-acylsphingosines Chemical class 0.000 description 1
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical class CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 description 1
- 101100202428 Neopyropia yezoensis atps gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- WNFHGZLVUQBPMA-JSCKKFHOSA-M Sodium glucuronate Chemical compound [Na+].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O WNFHGZLVUQBPMA-JSCKKFHOSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004110 Zinc silicate Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940102253 isopropanolamine Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical class CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- RUOPINZRYMFPBF-UHFFFAOYSA-N pentane-1,3-diol Chemical compound CCC(O)CCO RUOPINZRYMFPBF-UHFFFAOYSA-N 0.000 description 1
- UFEJXQWSRLAIOY-UHFFFAOYSA-N phenyl 1h-benzimidazole-2-sulfonate Chemical class N=1C2=CC=CC=C2NC=1S(=O)(=O)OC1=CC=CC=C1 UFEJXQWSRLAIOY-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000058 polyacrylate Chemical class 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical class OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JYKSTGLAIMQDRA-UHFFFAOYSA-N tetraglycerol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO JYKSTGLAIMQDRA-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
[Problem] To provide a vesicle composition having excellent stability over time, and an external skin preparation and a cosmetic, each containing the same.[Solution][1] A vesicle composition comprising a vesicle having a constituent membrane containing (A) an ether-based nonionic surfactant having a sterol skeleton and (B) a monoalkyl glyceryl ether.[2] An external skin preparation and a cosmetic, each comprising a vesicle composition containing a vesicle having a constituent membrane containing (A) an ether-based nonionic surfactant having a sterol skeleton and (B) a monoalkyl glyceryl ether.
Description
VESICLE COMPOSITION, AND EXTERNAL SKIN PREPARATION AND
COSMETIC, EACH CONTAINING SAME
Technical Field fooo1]
The present invention relates to a vesicle composition, and an external skin preparation and a cosmetic, each containing the same.
[0002]
Vesicles (closed cavities of an amphipathic substance, having a bimolecular membrane structure) are attracting attentions as a carrier, for example, for use in drug delivery system, as they incorporate active ingredients therein because of their specific structure.
[0003]
Typical known amphipathic substances constituting the vesicle include biological phospholipids (see, for example, Patent Documents 1 and 2). Vesicles of such phospholipids, which are also called liposomes, are natural components and thus intensively studied because of their biological safety. However, phospholipids are easily influenced by pH, temperature and also by electrolytes and there are many restrictions based on stability over time when they are used (see, for example, Nonpatent Document 1).
Thus, Nonpatent Document 1 cites castor oil, soy bean oil, arginine, methionine, cholesterol, phytosterol, casein, monoglycerides, and diglycerides as the additive for stabilization.
In addition, known for improvement of storage stability when blended with electrolytes are cosmetic liquid emulsion preparations containing lysophospholipids, oils such as glyceryl tri(2-ethylhexanoate), cosmetic electrolytes, water, and additionally polyoxyethylene sterol ether (see, for example, Patent Document 3).
Alternatively, vesicles of a non-ionic synthetic surfactant such as a polyoxyethylene hydrogenated castor oil ether or a polyoxyethylene castor oil ether, which was used as the amphipathic substance other than phospholipids, were proposed (see, for example, Patent Document 4).
Patent Documents
[0004] [Patent Document 1] Japanese Unexamined Patent Application
Publication No. 2010-59066 [Patent Document 2] Japanese Unexamined Patent Application
Publication No. 2008-88133 [Patent Document 3] International Patent Application Publication
No. WO 2005/77322 pamphlet [Patent Document 4] Japanese Unexamined Patent Application
Publication No. 59-16534
Nonpatent Document
[0005] {Nonpatent Document 1] "development of advanced cosmetics,”
P.122-123, (2000)
[0006]
However, phospholipids are compounds generally having fatty acids bound to the C-1,2 position of the glycerol skeleton by ester linkage. For that reason, phospholipids contained in a vesicle system are often hydrolyzed gradually over time, consequently releasing free fatty acids. In addition, the free fatty acids often lower the pH of the system and additionally reduce the dispersion stability of the vesicle. Additionally, the free fatty acids yellow the product and generate odor, leading to deterioration of product quality. Accordingly, although phospholipids are superior in the incorporation efficiency of scarcely water-soluble substances, and the penetration and storage efficiency in the skin, they are easily influenced by to external factors such as electrolytes and pH and contain an important problem of low stability over time.
In addition, they have a problem that they are less stable over time, even if a nonionic surfactant such as polyoxyethylene hydrogenated castor oil ether or polyoxyethylene castor oil ether is used, as will be shown in
Comparative Example 3 below.
Thus, there exists a need for studies aimed at improving the stability of vesicles over time.
[0007]
An object of the present invention, which was made under the circumstance and to solve the problems above, is to provide a vesicle composition superior in stability over time and an external skin preparation and a cosmetic, each containing the same.
[0008]
After intensive studies to solve the problems above, the inventors have found that it was possible to form a novel vesicle superior in stability over time, especially salt resistance and acid/alkali resistance, by using a vesicle composition containing an ether-based nonionic surfactant having a sterol skeleton and a monoalkyl glyceryl ether. It was also found that, if such a vesicle composition is used, the stability of the vesicle is easily retained even when it is used in an external skin preparation or a cosmetic normally containing electrolytes.
[0009]
Thus, the present invention relates to the following inventions [1] to [71.
[1] A vesicle composition including a vesicle having a constituent membrane containing (A) an ether-based nonionic surfactant having a sterol skeleton and (B) a monoalkyl glyceryl ether.
[0010]
[2] The vesicle composition according to [1], wherein the membrane component contains a vesicle-forming auxiliary additionally as component (C).
[0011]
[3] The vesicle composition according to [2], wherein the vesicle-forming auxiliary is one, two or more compounds selected from sterols and ceramides.
[4] The vesicle composition according to [2] or [3], wherein the content ratio of the component (A) to the component (C) by mass, (A):(C), is 1:4 to 4:1.
[5] The vesicle composition according to any one of [2] to [4], wherein the content ratio of the total mass of the components (A) and {(C) to the mass of the component (B), ((A)+(CH:(B), is 12:1 to 1:12.
[0012]
[6] An external skin preparation including the vesicle composition according to any one of [1] to [5].
[7] A cosmetic including the vesicle composition according to any one of [1] to [5].
[0013]
The present invention provides a vesicle composition superior in the stability of the vesicle over time and an external skin preparation and a cosmetic, each containing the same.
[0014]
Fig. 1 shows the result obtained by small-angle X-ray scattering (Saxs) measurement of the vesicle composition according to the present invention,
Fig. 2 shows the result obtained by transmission electron microscope
(TEM) observation of the vesicle composition according to the present invention.
Fig. 3 shows the result obtained by differential scanning calorimetry (DSC) measurement of the vesicle composition according to the present mvention.
Fig. 4 shows the result obtained by fluorescence polarization measurement of the vesicle composition according to the present invention.
Fig. 5 shows the result obtained by fluorescence polarization measurement of the vesicle composition of a Comparative Example.
Fig. 6 shows the result obtained by fluorescence polarization measurement of the vesicle composition of another Comparative Example.
[0015]
The vesicle composition according to the present invention comprises a vesicle having a constituent membrane containing a component (A) an ether-based nonionic surfactant having a sterol skeleton and a component (B) a monoalkyl glyceryl ether.
[0016]
The component (A) of the present invention, i.e., the sterol skeleton-containing ether-based nonionic surfactant, is for example a polyoxyalkylene sterol ether and examples thereof include adducts of alkylene oxide to a sterol skeleton such as phytosterol skeleton or cholesterol skeleton. Because the component (A) is used mainly as the component forming the vesicle membrane, the vesicle composition is resistant to hydrolysis even under acidic or alkaline condition and thus improved in stability over time.
[0017]
Examples of the structures of the sterol skeleton region include animal-derived sterol skeletons such as cholesterol, cholestanol, lanosterol, cerebrosterol, dehydrocholesterol and coprostanol; plant-derived sterol skeletons such as B-sitosterol, stigmasterol, campesterol and ergosterol, fucosterol, spinasterol, and brassicasterol; microbe-based sterol skeletons such as mycosterol and zymosterol; and the derivative thereof for example by hydrogenation or hydration.
Those having animal-derived sterol skeletons are obtained mainly from animals. They are prepared, for example, from wool fat, and examples thereof include lanolin alcohols containing cholesterol and lanosterol as the principal components, or the hydrogen adducts thereof, and the like.
Those having plant-derived sterol skeletons are obtained mainly from plants. Phytosterols are generally one, two or more compounds selected from B-sitosterol, stigmasterol, campesterol, fucosterol, spinasterol, brassicasterol, and ergosterol, and in particular a mixture of two or more compounds.
[0018]
Examples of the alkylene oxides to be added to the sterol include alkylenes having a carbon number of 2 to 5, such as ethylene oxide, propylene oxide, butylene oxide, and ethylene-propylene oxides. The average mole number of the alkylene oxides added is preferably 3 to 40, more preferably 5 to 30, and more preferably 5 to 10.
They may be used alone or in combination of two or more.
[0019]
In particular, those with ethylene oxides added to the sterol skeleton (also referred to as "POE sterols") are preferable. The sterol skeleton and the average mole number of ethylene oxide added are the same as those described above. Hereinafter, they can be used alone or in combination of two or more.
More specific examples thereof include polyoxyethylene cholesteryl ethers such as POE (5) cholesteryl ether, POE (10) cholesteryl! ether, POE (15) cholesteryl ether, POE (20) cholesteryl ether, POE (24) cholesteryl ether, and POE (30) cholesteryl ether: polyoxyethylene cholestanols such as POE (20) cholestanol, POE (25) cholestanol, and POE (30) cholestanol; polyoxyethylene phytosterols such as POE (5) phytosterol, POE (10) phytosterol, POE (20) phytosterol, POE (25) phytosterol, and POE (30) phytosterol; polyoxyethylene phytostanols such as POE (20) phytostanol,
POE (25) phytostanol, and POE (30) phytostanol, and the like. The numbers in parenthesis of the typical examples above are the average mole number of the ethylene oxides added. The same shall apply hereinafter.
In particular, polyoxyethylene cholesteryl ethers and polyoxyethylene phytosterols are preferable from the point of stability over time. More preferable are POE (5 to 30) cholesterols and POE (5 to 30) phytosterols. Further preferable are POE (5 to 10) cholesterols and POE (5 to 10) phytosterols.
[0020]
The amount of the component (A) sterol skeleton-containing
~ ether-based nonionic surfactant used in the present invention is not particularly limited, but preferably 0.01 to 10 mass %, more preferably 0.05 to 5 mass %, still more preferably 0.1 to 0.5 mass %, further more preferably 0.3 to 0.5 mass %, with respect to 100 mass % of all components used in preparing the vesicle composition (hereinafter, referred to also as "total amount used"), from the point of stability over time. -
[0021]
The component (B) monoalkyl glyceryl ether according to the present vention is a derivative of glycerol etherified at the site-1 hydroxyl group.
Because the component (B) is mainly used as the component for the vesicle membrane, the vesicle composition is resistant to hydrolysis even under acidic/alkaline condition and superior in stability over time.
For example, those represented by the following Formula are preferable.
[0022]
R-O-CH: CH(OH)-CH:0H (wherein, R is a linear or branched alkyl group having a carbon number of 6 to 30).
[0023]
The alkyl group is preferably a linear or branched alkyl group having a carbon number of 8 to 24. Examples of such components (B) include batyl alcohol, chimyl alcohol, selachyl alcohol, monobehenyl! glyceryl ether, mono-2-ethythexyl glyceryl ether, monoisostearyl glyceryl ether, monocapryl glyceryl ether, monoisodecyl glyceryl ether, and the like.
Among them, those with an alkyl group having a carbon number of
12 to 22 are preferable and those having a carbon number of 16 to 22 are more preferable. Further among the components (B) above, batyl alcohol, chimyl alcohol, and selachyl alcohol are preferable.
The amount of the component (B) monoalkyl glyceryl ether used in the present invention is not particularly limited but preferably 0.01 to 5 mass %, more preferably 0.1 to 2 mass %, still more preferably 0.1 to 1 mass %, further more preferably 0.1 to 0.9 mass %, and yet more preferably 0.1 to 0.3 mass % with respect to the total amount used from the point of stability over time.
[0024]
The vesicle composition preferably comprises a component (C) vesicle-forming auxiliary from the point of stability over time.
The component (C) vesicle-forming auxiliary used in the present invention is a vesicle membrane forming component added to facilitate vesicle formation and improve the stability over time, and examples thereof include sterols and ceramides. They may be used alone or in combination of ) two or more. The sterols are preferably those insoluble in water but readily soluble in organic solvents such as lower alcohol.
[0025]
Known sterols can be used as the sterols and examples thereof include animal-derived sterols such as cholesterol, cholestanol, lanosterol, cerebrosterol, dehydrocholesterol, and coprostanol; one, two or more phytosterols selected from B-sitosterol, stigmasterol, campesterol, fucosterol, spinasterol, brassicasterol, and ergosterol; plant-derived sterols such as
Macadamia nuts oil fatty acid cholesteryl and palm oil fatty acid cholesteryl:
microbe-derived sterols such as mycosterol and zymosterol; and the derivative thereof for example by hydrogenation or hydration.
In particular, animal- and plant-derived sterols are preferable; cholesterol and phytosterols are more preferable from the points of salt resistance and acid/alkaline resistance; and phytosterols are further more preferable. Generally cholesterol and phytosterols have low affinity to water and are thus oleophilic. More specifically, they are hardly soluble in water and soluble in organic solvents (such as lower alcohols having a carbon number of 1 to 3 {e.g., monovalent, bivalent).
The sterols described above may be used alone or in combination of two or more.
[0026]
The ceramides above may be known ceramides and examples thereof include natural ceramides, synthetic ceramides, and pseudoceramide (synthetic pseudoceramide), and the like. Such ceramides are favorable from the points of stability over time and also from the efficiency to raise moisturizing action.
It is preferable to use synthetic ceramides and/or pseudoceramides, because they can be produced at low cost and the purity of them can be adjusted readily. Typical examples thereof include N-acylsphingosines,
N-hydroxyacylphytosphingosines, N-acylphytosphingosines, type-1 to -4 ceramides, and the like. In particular, N-stearoylsphingosines (ceramide 2) are preferable.
The ceramides described above may be used alone or in combination of two or more.
[0027]
The amount of the component (C) vesicle-forming auxiliary used in the present invention is not particularly limited, but preferably 0.001 to 3 mass %, more preferably 0. 05 to 2 mass %, still more preferably 0.05 to 1 mass %, further more preferably 0.05 to 0.5 mass %, particularly 0.2 to 0.5 mass %, yet particularly 0.3 to 0.5 mass % with respect to the total amount used, from the point of stability over time.
[0028]
The content ratio of the component (A) to the component (C) by mass, (AC), then is not particularly limited, but preferably 1:4 to 4:1, more preferably 1:2 to 2'1, further more preferably 2:3 to 3:2, from the points of stability over time, especially of salt resistance and acid/alkaline resistance. ~The content ratio of the total of the components (A) and (C) to the component (B) by mass is also not particularly limited, but the ratio ((A)+(C)):(B) is preferably 12:1 to 1:12, more preferably 9:1 to 1:9, still more preferably 6:1 to 3:7, further more preferably 5:1 to 3:2, particularly preferably 5:1 to 3:1, from the point of stability over time, especially of salt resistance and acid/alkaline resistance.
[0029]
The vesicle composition according to the present invention may contain electrolytes and scarcely-soluble substances as needed as other components (DD). The electrolytes are substances that dissociate into ions in solvents (in particular, water) and examples thereof include polyelectrolytes, low-molecular weight electrolytes, and the like.
These electrolytes are used, for example, for provision of pharmacological actions (for example, dermatologically effective beauty care), improvement of stability and storage life, adjustment of viscosity and pH, and the like. The dermatologically effective beauty care includes moisturization, inflammation prevention, skin-whitening, ultraviolet protection and the like. The scarcely-soluble substance is a substance that 1s not readily soluble in polar solvents and/or non-polar solvents and used, for example, for the pharmacological action described above and also for improvement of stability and storage life, and it is possible to incorporate such a substance in the vesicle.
[0030]
The electrolyte (low-molecular weight electrolyte and polyelectrolyte) used is not particularly limited and may be any compound, organic or organic, if it is commonly used as pharmaceuticals or cosmetics.
Examples thereof include, but are not limited to, salts of an alkali metal such as sodium or potassium, salts of an alkali-earth metal salt such as magnesium or calcium, and the like. The following electrolytes may be used alone or in combination of two or more.
[0031]
Examples of the low-molecular weight electrolytes for the moisturization application include inorganic electrolytes such as alkali-metal or alkali-earth metal salts including sodium chloride, magnesium chloride, calcium chloride, aluminum potassium sulfate, and sodium hydrogen phosphate; organic electrolytes such as organic acids, amino acids, and sugars including pyrrolidonecarboxylic acid salt, edetate salts, urea, citric acid, lactic acid, sodium lactate, citrate salts, lactate salts,
succinate salts, malate salts, L-alanine, B-alanine, L-arginine, L-arginine hydrochloride salts, L-asparagine monohydrate, L-aspartic acid, polyaspartic acid, L-citrulline, L-cysteine, L-cysteine hydrochloride salt monohydrate,
Lreystine, L-DOPA, L-glutamic acid, N-acylglutamic acid, L-glutamic acid hydrochloride, L-glutamine, polyglutamic acid, glutamate salts, glycine, trimethylglycine, L-histidine, L-histidine hydrochloride monohydrate,
L-hydroxyproline, L-isoleucine, L-leucine, L-lysine, L-lysine hydrochloride,
L-methionine, L-ornithine hydrochloride, L-proline, L-phenylalanine,
L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, Lra-aminobutyric acid, glucosamine hydrochloride, and sodium glucuronate; and the like.
Examples thereof for the inflammation prevention application include glycyrrhizate salts, glycyrrhetinate salts, salicylic acid, salicylate salts, and the like. Examples thereof for the skin-whitening and anti-oxidative applications include vitamins such as L-ascorbic acid, sodium
Lrascorbic acid-2-phosphate, magnesium L-ascorbic acid-2-phosphate,
L-ascorbic acid glucoside (e.g., Li-ascorbic acid 2-glucoside), vitamin A's such as tranexamic acid, vitamin B's, vitamin C, vitamin E and the like.
Examples thereof for the ultraviolet protection application include phenylbenzimidazolesulfonate salts, hydroxymethoxybenzophenonesulfonate salts, and the like.
[0032]
Examples of those for the pH (alkaline region) adjustment application include basic amino acids such as L-arginine; alkali or alkali-earth metal hydroxide or carbonate salts such as sodium hydroxide, potassium hydrexide, calcium hydroxide, magnesium hydroxide, and sodium carbonate; amines such as monoethanolamine, diethanolamine, triethanolamine, isopropanolamine, diisopropanolamine, triisopropanolamine, and 2-amino-2-methyl-1,3-propanediol; and the like.
Examples of those for the pH (acid region) adjustment application include acidic amino acids such as L-aspartic acid and glutamic acid; organic or mineral acids such as lactic acid, malic acid, citric acid, tartaric acid, acetic acid, succinic acid, phosphoric acid, hydrochloric acid, sulfuric acid, and nitric acid: and the like .
[0033]
Among the low-molecular weight electrolytes above, inorganic electrolytes (in particular, alkali-metal salts), organic electrolytes (in particular; organic acids), and vitamins (in particular, vitamin C's) are preferable.
[0034]
Examples of the polyelectrolytes for example for the moisturization, skin-whitening, and antioxidation include animal-derived polysaccharides (acidic mucopolysaccharides, basic polysaccharides, ete.) such as hyaluronate salts and chitosan hydrochloride or the glycopeptides thereof, plant-derived polysaccharides such as galactomannan, seaweed-derived polysaccharides such as carrageenan: microbe-derived polysaccharides such as xanthan gums nucleic acids such as DNA salts; polyacrylate salts, and the like.
[0035]
The vesicle composition according to the present invention may contain physiologically active substances such as enzymes, peptides, hormones, cell growth factors, placenta extracts, ATP, cyclic ATPs,
interferons, vitamins, royal jelly, microbial metabolites, prostaglandins, sphingosine derivatives, astaxanthine, and sugars, as they are incorporated in the vesicle particles in the range that does not impair the advantageous effects of the present invention. In addition, the vesicle composition according to the present invention may contain various additives such as surfactants, water-soluble polymers, in addition to the components above.
[0036]
The production method for the vesicle composition according to the present invention is not particularly limited and it may be produced by any general method. It can be prepared, for example, by vortexing method (A. D.
Bangham, J. Mol. Biol., 13. 238 (1965)), sonication method (C. Huang,
Biochem., 8, 344 (1969), prevesicle method (H. Trauble, Neurosci. Res. Prog.
Bull, 9, 273 (1971), ethanol-injection method (S. Batzri, Biochem. Biophys.
Acta., 298, 1015 (1973), French press-extrusion method (Y. Barenholz,
FEBS Lett., 99, 210 (1979), cholic acid-removal method (Y: Kagawa, J. Biol.
Chem. 246, 5477 (1971)), Triton X-100 batch method (W. J. Gerritsen. Eur. J.
Biochem., 85, 255 (1978)), Ca?* fusion method (D. Papahadojopoulos,
Biochem. Biophys. Acta., 394, 483 (1975), ether-injection method (D.Deazer,
Biochem. Biophys. Acta., 443, 629 (1976), annealing method (R. Lawaczeck,
Biochem. Biophys. Acta., 443, 313(1976)), freeze/saw fusion method (M.
Kasahara, J. Biol. Chem., 252,7384 (1977), W/O/W emulsion method (S.
Matsumoto, J. Colloid Interface Sci., 62, 149 (1977), reverse-phase evaporation method (F. Szoka, Proc. Natl. Acad. Sci. USA, 75, 4194 (1978), polyvalent alcohol method (JP-A No. 60-7932) or the like.
[0037]
The vesicle composition according to the present invention is produced, for example, by using the components (A) and (B) and as needed the component (C) as the major components for the membrane of the vesicle particles, adding any other components as needed, forming vesicle particles of these components, and thus giving a vesicle composition.
Specifically, the vesicle composition is prepared by mixing the components (A) and (B) and additionally a component (E)} dispersing solvent, dispersing these components under heat and agitation, and allowing the dispersion to cool to room temperature and thus forming vesicle particles.
The component (BE) dispersing medium is not particularly limited and, for example, purified water and/or a hydrophilic organic solvent may be used.
In particular, it is preferable to use purified water and a hydrophilic organic solvent in combination for preparation of the vesicle.
The concentration of the vesicle components, with respect to 100 mass % of the all components used for the vesicle composition can be adjusted by using the component (E) dispersing solvent (preferably purified water).
[0038]
More specifically, the vesicle composition according to the present invention is obtained by dispersing the components (A) and (B) in a component (E) hydrophilic organic solvent by agitating the mixture under heat at a temperature of 70°C or higher (preferably about 90 to 100°C) for about 2 to 10 minutes, adding a component (E) purified water to the dispersion, stirring the resulting dispersion at a temperature kept at 70°C or higher (preferably 70 to 80°C) for about 2 to 10 minutes, and cooling the mixture gradually to room temperature (about 20 to 40°C).
When the components (C) and (D) are mixed with the components (A) and (B), it is preferable to add the components (C) and (D) to a component (E) hydrophilic organic solvent. Alternatively, the component (D) may be added to the component (E) purified water.
[0039]
Examples of the component (E) hydrophilic organic solvents include alcohols such as monovalent and polyvalent alcohols.
The monovalent alcohols are, for example, lower alcohol having a carbon number of 1 to 3 (for example, ethanol).
The polyvalent alcohol above has two or more hydroxyl groups in the molecule. Examples of those having two hydroxyl groups in the molecule (bivalent alcohols) include polypropylene glycols such as propylene glycol, dipropylene glycol, and tripropylene glycol; butylene glycols such as 1,3-butylene glycol and 1,4-butylene glycol; pentanediols such as 1,2-pentanediol and 1,3-pentanediol, and the like. Examples of those having three or more hydroxyl groups in the molecule include glycerol, polyglycerins such as diglycerin, triglycerin, and tetraglycerol: polyethylene derivatives, and the like.
[0040]
Among the alcohols above, polyvalent alcohols are preferable; among them, bivalent alcohols are preferable; butylene glycols, especially 1,3-butylene glycol, are preferable for providing a vesicle superior in stability over time,
[0041]
The alcohols above may be used alone or in combination of two or more. The amount of the alcohol used is not particularly limited, but preferably at least thrice larger (by mass) than the total amount of the components (A) and (B) or components (A) to (C). More specifically, it is preferably 0.01 to 50 mass %, more preferably 0.1 to 20 mass %, still more preferably 1 to 10 mass %, particularly 3 to 8 mass % with respect to the total amount used.
[0042]
Vesicle particles formed with conventional vesicle compositions (in particular, vesicle compositions containing phospholipid) were lower in salt resistance and acid/alkali resistance and thus unfavorable in stability over time.
In contrast, as shown in Examples below, it is possible to form a new vesicle by using the components according to the present invention, even if no phospholipid is used. The vesicle formed according to the present invention can accommodate electrolytes, scarcely-soluble substances and others therein and thus can be used, for example, for transportation of active ingredients in the body and for improvement of penetration and storage of such an active ingredient in the skin.
The vesicle according to the present invention is stable thermodynamically, even if there are electrolytes inside or outside the vesicle (for example, in the copresence of a basic/acidic drug, high-conductivity solution, alkaline solution, or acidic solution). It is thus very excellent in stability over time. It is also superior in membrane flowability, which makes it possible to make an active ingredient penetrate and stored in the skin and to enhance the action of the active ingredient.
[0043]
For that reason, the vesicle composition according to the present invention can be used in wide application shapes and can incorporate various active ingredients internally. In particular, they ave possibly superior in stability over time, even if the electrolytes described above are contained in the vesicle composition. The vesicle according to the present invention is expected to have the operations and effects of the further electrolytes and scarcely-soluble substances and show not only its inherent vesicle characteristics, but also the synergic effect. Because the components (A), (B), and (C) are inexpensive, reliably available raw materials, it is possible to provide the vesicle composition inexpensively and reliably. It is thus possible to use it in wide areas, including the areas of pharmaceuticals, external skin preparations, and cosmetics, by making the most of the favorable characteristics of the vesicle.
[0044]
The vesicle composition according to the present invention preferably has a pH (20°C) of 2 to 11, more preferably 3 to 10. As described above, the vesicle composition according to the present invention is superior in stability over time not only in the neutral region of 6 to 7, but also in an acidic region of 3 to 5 and an alkaline region of 8 to 10.
The vesicle composition normally has an electric conductivity (20°C) of less than about 0.001 S/m. Even if electrolytes are present, i.e., even if the vesicle composition according to the present invention has an electric conductivity higher than that of normal vesicle, for example in the range of
0.001 to 3 S/m, more specifically 0.001 to 1 S/m, further 0.001 to 0.5 S/m, it is advantageously superior in stability over time compared to conventional vesicle compositions. The electric conductivity is a value determined at 20°C by using a conductivity meter.
[0045]
The vesicle composition according to the present invention described above can be used, as it is, in various applications, for example as pharmaceuticals, quasi drugs, external skin preparations, and cosmetics.
The vesicle composition according to the present invention may be used, as it is contained in products in the various applications above, and the content of the vesicle composition according to the present invention therein is not particularly limited, but is preferably 1.0 to 90 mass %, and more preferably 3.0 to 50 mass % in the product. The ranges of pH and electric conductivity of the product are advantageously in the ranges described above from the point of the stability of vesicle over time.
[0046]
The method of producing the product is not particularly limited, and it can be produced for example by preparing a vesicle composition and then mixing it with any other components. Alternatively, it is also possible to obtain the vesicle composition, simultaneously as the product is prepared in accordance with the method of producing the vesicle composition as described above.
[0047]
In addition, various additives normally used in the pharmaceuticals, external skin preparations, and cosmetics described above (e.g., water,
alcohol, oils, surfactants, thickeners, powders, chelating agents, pH adjusters, moisturizers, whiteners, various drugs such as antiinflammatory agents and cell activators, plant-, animal, and microbe-derived extracts, flavoring agents, and the like) may be used as other arbitrary components in the range that does not impair the advantageous effects of the invention.
[0048]
The product according to the present invention may be used in any shape. The vesicle composition according to the present invention is higher in skin permeability, which is a characteristic inherent to vesicles, and thus preferably used in external skin preparations and cosmetics.
Examples of the forms of the external skin preparations and cosmetics used include cosmetics in the forms of emulsion, cream, skin lotion, beauty-care liquid, pack, cleaning agent, and make-up cosmetics, external drugs in the forms of dispersion, ointment, liquid, aerosol, patch, poultice, and hiniment.
[0049]
Hereinafter, the present invention will be described specifically with reference to Examples and Test Examples, but it should be understood that the present invention is not restricted by these Examples.
[0050] (Vesicle compositions of Examples 1 to 15)
Vesicle compositions were prepared by using the components shown in the columns of Examples 1 to 15 of Table 1 by the following production process.
A vesicle composition of Example 13 (sample B in Fig. 3) was prepared in a manner similar to that of the vesicle composition of Example 2 (sample A in Fig. 3), except that the contents of the component (A) polyoxyethylene (5 mole) phytosterol, the component (B) batyl alcohol, and the component (C) cholesterol were altered.
Step 1: Components selected from the components 1 to 17 were fused into a solution under heat at 95°C.
Step 2° Purified water was added to the solution obtained in step 1, as the mixture was kept constant at 75°C, and the mixture was agitated in a dispermixer, to give a dispersion.
Step 3: The dispersion obtained in step 2 was cooled gradually to 40°C, to give each of the vesicle compositions of Examples 1 to 15.
[0051]
The pH (20°C) of each vesicle composition obtained was approximately 4 to 5 and the electric conductivity (20°C) was equal to or less than 0.001 (S/m).
[0052] (Vesicle compositions of Test Examples 1 to 3)
As shown in the columns of Test Examples 1 to 3 of Table 2, components selected from the components 18 to 20 were added to the vesicle compositions obtained by the production processes 1 to 3, to give vesicle compositions of Test Examples 1 to 3.
The vesicle composition of Test Example 1 had an electric conductivity (20°C) of 0.36 (S/m).
The vesicle composition of Test Example 2 had a pH (20°C) of 3.2 and an electric conductivity (20°C) of 0.07 (S/m).
The vesicle composition of Test Example 3 had a pH (20°C) of 9.7 and an electric conductivity (20°C) of 0.03 (S/m).
sk — i w = ~ ww = In “lm wn = a = a 2 «x & z i i 5 aT = $ Pod G0 dul 2 one: = “3 2s = : ? =3 = o ied Ellon <= PS © 5 ER a | i £ A — on - off | Biron 412.8 135 <= = wi =i <p pi 2
SEE
— ¢ g EZ - a. 2 26 tt = z - 27 M . Hf ee i oe al Ea 8 : 7 2 Moe & “ 5 < |] Bolo laels i= <= . : Po Mi Hi), To = = = = © Eat 8S Z A “ ~ 5 + a2 @
El lz ZT 2 = = 3 fad re) filed] <jmflZ 8 F = o «= =0 ol ed ERE ! +; j : iS doa i = = DT
EF ow
Is : ECS
HY ~
Hl = = No i <TH
Ml : ROL “ g : i To 2 218 © 5) | |<im«li 22 o = el | Ai : = 2H
TUE
ZH i=l [a ® iol =~ od yf ert 4 . ? i <0 o
Wf it od = : wo] = Sli =| | <clen] < < @ 2) 1%
Joa) 3 10 - LL |e la Bimlo on) < «13 3 3 EE oi a : i ; ¢ ! ~ : i “lg s < = = wn o - ~ = wo 5D ip
A 2H A750 oy A i —_— 8 |x ge =] x 1) 8 = THA GT nd od = = i =f 5 od & °oo~ . © Pe bn
EES i SE i i Coda = ; oe 4 i & s3E¢ i = | i I 2288 —_ I FEE
Fle ! i i HE = 82H == 3 ] HI 55% E
Fo | 8 = IRR
TEE 8 | E le EEF =a] el i ig. a 8 mie ol FC] O co i! Lomo mm NY Df SS = . & S EEE
ClEfElg|w glo | & 2 Z = ofl wl of | | d Bon
Sill] Eleaf BLE PIE & oo — Eile 2 2
SiR Ha SRS gl al 2 = 0 - En gED Elae wo QD @ 5 | og Q — eg ow £22237 = Sf 21g Mo 35 @ a 2S slg ga SES gsc ag
EEE EEE ; hE [B28 E32 gE zig seal dB CiEl~ gp E BET = al oda 58 © OT mE RB] EE BEE = Bf re |e | OD fm {TTA - Ll ol S18 EB Ee
S |=2EeE ne 2 0 12 ESE Eee 28S
DET ~l. =] ' OAD
SB 8g Elsie 8 VS ZV] S75 Elen on gp
Si EE 2 EBlhE : 5 Peg SBA aEaw eo Tole yl 5 (ol 22 IsiclgmeEn© wlio 8] wld ot [= =i mim of pe = mt] Se | md a | et of Diag “ gl | 2 Pm ded F i | oo ef el eo a & — 5 oH EE wl BRIO OM
EIR EE I NS Sis i = ai sl of 4 EAR i jp & Dol aia) oi BLES 5 a ®/ 41 Blo ; on yu miei] gy giaie = @f & =| 5 TIE gi ee
Be Bed Bgl Be S81] ele & = < Bgl eis Es 02 = Seg gle] Bll gi ggl ala 8 gl oll = El 3 = Zoe oS = EE EE EE EER Ro Lo FIRE ibe IRE {ES Eg i i Sy Br Rimi LR DEES EEE TH wm llr og on =
SE gar Has EEE A= 8 8E< 255 E5855 Seerres
SEES BER El glEl 5 ef 8 EEE 58 £55
FEES ERE SSE BE AE ERB EEEE Sicles
Clo o Siw = = 3
SEIS SE 25 281810] ISR S E25 Fa) 5 E) ETE
Bl Pll Blea ina 2ionlmlelala] B 2 22222822288 8000282288 82 SEE 3 - ei wehiol ole wl ol of rhe te
E1SRNRRRRRRE > = ale = = EEEEERER slim 2
~ = = ol 2 1] = 3 = i= Ng i Cojo Ho = ht =m fi wed 2 EET = i — 0 s wl Z) og 4 = i Ng 1 moose = = S| “Ee
E A | 35 .E @ i FE oS fi = ol fi iS 0H 3 : pp © Sg LL olo|oiE EZ & ol a8 | S| 5 Ed: g =| ¥
ES | of p 5 | EN
Ele == 0 & olo|olE $2
EHS =e el = Eg
Pe ) | x2 = 8
I. 25% 8 = oN He in § vjwo| ZTE oR o = = =i E22 © od EZ ! B= 2 232 <= | | : = Z = iw 2 Pol 38 ! Bl S = STH @ Fa hele & ] =00 = = io =| Clegg - = = = gE el] = [SSA 8 | WP I= : ao = ER 2 a = © S| gf «jm = © ws = os Sz © 2 g | 3
BH pi | ed 5 = = — 1 hei |p | tt
Hic 2 o <0 © = wl jeal <= | 3 ow ! wy 2 | ! 8 i [1m]
THz 2 2 ole] |S EDIT (aml < a = = slg ed i =H] anni = i GE = R SE. = EE 9 | |g EET
Tal B = # E23
T 3 : ~~
MELB W B g SEE 32 52 3g | |2EES moe 28 64 § 18 EEE
TEE Se EY | 2 £ £5353
Lill 8 2 0g - i 2 ig ETC E
E557 Bs i 2 o Lom oET
Sal gS o = i Po =] | Edo 2 olalE mg 8s | CELE |S
Elzizlgig slg | ; : SIZE gfe Ed = 81% 7
PEI SIE wig Big IEE 18s EE = Bl 2172 oy =lg| = clEES 8
SEE ES EE © cS EFPEEEE
Pals Sil E | = pole Bla 2 Bn i258 28 | BE Pofa 55 RES es o 212g] ET < & Prgleia els 2 B02 x z —_1 2 CIE EFISS EE 2| BE 2 BE g S gl & 7 a= 8E3
Elala| Elog EE = | oi fu HOSE 8 ET a ward 1 TE I } ElEBIg IE oy So uD} e- SE © i g a2 wim gl ag g = | 218 Bolzegs or fr who — 2 = h gS TolBE SEE
QED RD REE BE © = I HRB BRE 22838 52-42 ol Bl [EBT] (Sle gl ETE — = & ol A
EEE EEE REE RE EE EE eT £5555 838552838848 gl5E HALES THe we Do 8 Sle ©] Bl Bl @[21E|=I88 =o = A u
EERE LE EEE EEE EEE EEE EE SocREEn = mom i - :
EEE EEE EEE EE SEES EEE EE E SINE 3 3
EN SHEER E52 HEE EER REE Es fice 8g A 2, SEES EEE E SEAS Sa0|a Al 2 E SHES
SESE EE 21= 3 i Sie SS =
X =| 8 EERE ee 500 feaake ds EE EEEEs wo 2 S SIE EEzEEE SCC EaE Bc SoHE wi OF] 00 | am | eo en
[0055] (Vesicle compositions of Comparative Examples 1 to 7)
Vesicle compositions of Comparative Examples 1 to 7 were prepared by using the components shown in the column of Comparative Examples 1 to 7 of Table 2 by the production process of the Examples 1 to 15.
[0056] (Tests for confirmation of maltese cross image by vesicle composition and on stability over time)
For first screening, samples immediately after production and after storage still at 40°C for 2 weeks were observed under the crossed Nicol of an polarization microscope (produced by Olympus Corporation) for determination of whether there were maltese cross images observable from the respective vesicle composition. The criteria for judgment are shown below and the results in Table 1.
In addition, each vesicle composition was observed under microscope after it is stored still at 40°C for 2 weeks in order to determine whether there is precipitation. :
[0057] (1) Criteria of maltese cross image
A: There were many maltese cross images observed
B® There were maltese cross images easily observable, although the number was not many.
C: There was no maltese cross image observed. (ii) Criteria of precipitation
A: There was no precipitation observed.
B: There was precipitation observable under microscope, but the amount thereof ig limited.
C: There was intensive precipitation observed, possibly causing problems
[0058]
The vesicle composition of Example 2, which was superior in stability over time, was subjected to small-angle X-ray scattering spectrum measurement in a high-brightness small-angle X-ray scattering device SAXS (produced by Anton Paar). As shown in Fig. 1, the vesicle composition showed peaks characteristic of lamellar structure in the small-angle X-ray scattering spectrum.
In addition, the presence of multilamellar vesicles was examined by using a transmission electron microscope (TEM) (phosphotungstic acid coating). As shown in Fig. 2, the TEM observation also gave a multilamellar vesicle image indicating a multilayer structure.
[0059]
The results above demonstrate that the vesicle compositions according to the present invention (vesicle compositions of Examples 1 to 15 and Test Examples 1 to 3) had a muttilamellar structure. They also exhibited excellent stability over time.
[0060] (Test for confirmation of thermodynamic stability of vesicles)
The vesicle compositions of Examples 2 and 13 were subjected to differential scanning calorimetry (DSC) in a heat-flux differential scanning calorimeter (SII NanoTechnology Inc.) The samples of Example 2 and 13 were referred to respectively as samples A and B.
Vesicle compositions of Examples 2 and 13 did not have the endothermic peak corresponding to the gel/liquid crystal transition temperature in the vicinity of 40 to 50°C, suggesting that they had a thermodynamically stable structure.
The results above suggested that the vesicles according to the present invention (vesicle compositions of Examples 1 to 15 and Test
Examples 1 to 3) are thermodynamically stable.
[0061] (Influence of electrolytes on vesicle compositions according to present invention)
The results of the tests on the vesicle compositions of Test Examples 1 to 3 according to the evaluation criteria (i) and (ii) are shown in Table 1.
Separately, NaCl was added to the vesicle composition of Example 2 to a concentration of 0.5 mass % and the stability over time of the mixture when stored at 50°C for 14 days was examined by monitoring the transmission coefficient. There was almost no change in transmission coefficient, indicating that the composition was favorably stable over time.
As shown in Test Examples 1 to 3, the vesicle compositions were favorably stable over time, even when an electrolyte, L-ascorbic acid 2-glucoside, citric acid, or sodium hydroxide, was added thereto.
As obvious from the results above, the vesicles according to the present invention (vesicle compositions of Examples 1 to 15 and Test
Examples 1 to 3) were superior in stability over time even in the copresence of electrolytes or in the acidic/alkaline region.
[0062]
(Tests on membrane flowability of vesicle)
The membrane flowability of the vesicle composition of Example 2 was examined by measurement of fluorescence polarization value.
Separately, vesicle compositions of Comparative Examples 8 and 9 were prepared similarly to the vesicle compositions of Comparative
Examples 6 and 7, except that L-ascorbic acid 2-glucoside and sodium hydroxide were not added, and the membrane flowability of them was evaluated. Each sample was adjusted to a NaCl concentration of 0, 0.3 or 0.5%.
The device used for determination of the fluorescence polarization value was a fluorescence photometer RF-5300 (manufactured by Shimadzu
Corporation). The reagents used were DPH (1,6-diphenyl-1,3,5-hexatriene, excitation light: 360 nm, fluorescence detection: 430 nm) as oleophilic fluorescence probe and ANS (I-anilinonaphthalene-8-sulfonic acid, excitation light: 380 nm, fluorescence detection: 465 nm) as hydrophilic fluorescence probe. The fluorescence polarization value was calculated according to the formula below and plotted along the left axis in Fig. 4 (DPH:o in Fig. 4, ANS: ¢in Fig. 4). In addition, the ratio (Pans/Popr) of the fluorescence polarization value (Poppi) when DPH was used to the fluorescence polarization value (Pang) when ANS was used was determined and plotted along the right axis of Fig. 4 (A in Fig. 4).
[0063] [Formula 1]
P=1y-10)/ d+ 11)]
P: fluorescence polarization value; Is: parallel polarization intensity: and I:
vertical polarization intensity
[0064]
It is thus possible to determine mobility of the hydrophilic and lipophilic groups in the vesicle, allowing evaluation of microscopic membrane flowability.
As shown in Fig. 4, in the case of the vesicle composition according to the present invention of Example 2, the Pans /Pppy remained almost without any change even when an electrolyte NaCl was added, indicating that the balance of membrane flowability by the hydrophilic and lipophilic groups are preserved.
On the other hand, as shown in Figs. 5 and 6, the vesicle compositions of Comparative Examples 8 and 9 had a significantly fluctuating Pans/Popy ratio. It indicates that the balance of membrane flowability by the hydrophilic and lipophilic groups is disturbed significantly by addition of an electrolyte NaCl and that the vesicle compositions were inferior to the vesicle compositions of the Examples.
Because the balance of membrane flowability in the vesicle particles according to the present invention was preserved, it is possible by using the vesicle according to the present invention to make an active ingredient penetrate and stored in the skin and enhance the action of the active ingredient.
[0065]
The results above demonstrated that the vesicle compositions according to the present invention (those of Examples 1 to 15 and Test
Examples 1 to 3) were superior in stability over time, particularly in salt ol resistance and acid/alkali resistance.
Thus, the vesicle composition according to the present invention is considered {o be a preparation that can possibly incorporate an active ingredient under a wide range of conditions.
It was also found that if is possible to form a vesicle, using at least a sterol skeleton-containing nonionic surfactant and a monoalkyl glyceryl ether as raw materials, even if phospholipids such as lecithin are not used substantially.
[0066]
Example 16: Ointment
An ointment was prepared with the components and by the production method described below.
[0067] (Component) (mass %) 1 Stearic acid 18.0 2 Cetanol 4.0 3 Triethanolamine 2.0 4 Glycerol 5.0
Dipotassium glycyrrhizate (Note 1) 0.5 6 Vesicle composition of Example 2 1.0 7 dl-a-Tocopherol acetate (Note 2) 0.2 & Methyl paraoxybenzoate 0.1 9 Purified water balance (Note 1) produced by Wako Pure Chemical Industries, Ltd. (Note 2) produced by Eisai Co., Ltd.
[0068] (Production method)
A: Components (3) and (4) and part of component (9) were mixed and kept under heat at 75°C.
B: Components (1), (2), (7), and (8) are mixed and kept under heat at 75°C.
C: B was added gradually to A; component (5) dissolved in the balance of component (9) was added, as the mixture was cooled; and component (8) was added thereto, to give an ointment.
[0069]
The ointment of Example 16 was an ointment superior in stability of the vesicle composition.
[0070]
Example 17 : Skin lotion
A skin lotion was prepared with the components and by the production method described below.
[0071] : (Component) (mass %) 1 Glycerol 5.0 2 1,3-Butylene glycol 5.0 3 Lactic acid 0.05 4 Sodium lactate 0.1
Monooleic acid polyoxyethylene (20 mole) sorbitan 1.2 6 Ethanol 8.0 7 Methyl paraoxybenzoate 0.1 & Flavoring agent 0.05
9 Vesicle composition of Example 3 10.0 10 Purified water balance
[0072] (Production method)
A: Components (5) to (8) were mixed, to give a solution.
B: Components (1) to (4) and (10) were mixed, to give a solution.
C:Awas added to and mixed with B; and component (9) was added thereto, to give a skin lotion.
[0073]
The skin lotion of Example 17 was a skin lotion superior in stability of the vesicle composition.
[0074]
Example 18: Emulsion
An emulsion was prepared with the components and by the production method described below. A
[0075] (Component) (mass %) 1 Monostearic acid polyoxvethylene (20 mole) sorbitan 1.0 2 Trioleic acid polyoxyethylene (20 mole) sorbitan 0.5 3 Glyceryl monostearate 1.0 4 Stearic acid 0.5
Behenyl alcohol 0.5 6 Squalane 8.0 : 7 Carboxyvinyl polymer 0.1 8 Methyl paraoxybenzoate 0.1
9 Sodium hydroxide } 0.05
Ethanol 5.0 11 Vesicle composition of Example 9 5.0 12 Purified water balance 13 Flavoring agent 0.05 14 Purified water 5.0
[0076] (Production method)
A: Components (7) to (9) were added to component (12) and the mixture was mixed uniformly at 70°C.
B: Components (1) to (6) were mixed uniformly at 70°C.
C: B was added to A and the mixture was emulsified and cooled to room temperature.
D: Components (10), (11), (13) and (14) were added thereto, and the mixture was mixed uniformly, to give an emulsion.
[0077]
The emulsion of Example 18 was an emulsion superior in stability of the vesicle composition.
Claims (7)
1. A vesicle composition, comprising a vesicle having a constituent membrane containing (A) an ether-based nonionic surfactant having a sterol skeleton and (B) a monoalkyl glyceryl ether.
2. The vesicle composition according to Claim 1, wherein the constituent membrane contains a vesicle-forming auxiliary additionally as component (C).
3. The vesicle composition according to Claim 2, wherein the component (C) vesicle-forming auxiliary is one, two or more compounds selected from sterols and ceramides.
4. The vesicle composition according to Claim 2 or 3, wherein the content ratio of the component (A) to the component (C) by mass, (4):(C), is 1'4 to 4:1.
5. The vesicle composition according to any one of Claims 2 to 4, wherein the content ratio of the total mass of the components (A) and (C) to the mass of the component (B), ((A+(C):(B), is 12:1 to 1:12.
6. An external skin preparation, comprising the vesicle composition according to any one of Claims 1 to 5.
7. A cosmetic, comprising the vesicle composition according to any one of Claims 1 to 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010243326 | 2010-10-29 | ||
PCT/JP2011/073999 WO2012056956A1 (en) | 2010-10-29 | 2011-10-19 | Vesicle composition, and external skin preparation and cosmetic, each containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG187808A1 true SG187808A1 (en) | 2013-03-28 |
Family
ID=45993669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013010277A SG187808A1 (en) | 2010-10-29 | 2011-10-19 | Vesicle composition, and external skin preparation and cosmetic, each containing same |
Country Status (7)
Country | Link |
---|---|
JP (1) | JP5074637B2 (en) |
KR (1) | KR101840037B1 (en) |
CN (1) | CN103079529B (en) |
HK (1) | HK1184065A1 (en) |
SG (1) | SG187808A1 (en) |
TW (1) | TWI423822B (en) |
WO (1) | WO2012056956A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6025676B2 (en) * | 2013-07-31 | 2016-11-16 | 株式会社ノエビア | Weakly acidic aqueous external composition containing Photosensitive Element 201 |
WO2016140473A1 (en) * | 2015-03-02 | 2016-09-09 | (주)아모레퍼시픽 | Multilamella nanoliposome which contains skin lipid components, and preparation method therefor |
JP6848200B2 (en) * | 2016-04-07 | 2021-03-24 | 大正製薬株式会社 | Ursolic acid-containing liposome dispersion |
KR101937699B1 (en) * | 2018-05-04 | 2019-01-11 | 코스맥스 주식회사 | Vesicle for enhancing the skin penetration, and preparation method of the same |
CN112351768A (en) * | 2018-09-28 | 2021-02-09 | 株式会社漫丹 | Composition for skin cosmetic |
JP7221030B2 (en) * | 2018-11-16 | 2023-02-13 | 株式会社ミロット | Method for producing liquid crystal composition |
JP7560983B2 (en) | 2019-09-20 | 2024-10-03 | 株式会社コーセー | Vesicle composition and cosmetic preparation containing same |
CN115554180B (en) * | 2022-10-24 | 2023-09-22 | 陕西畅想制药有限公司 | 4-butylresorcinol supermolecule vesicle aggregate, preparation method thereof and cosmetic composition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100439068B1 (en) * | 2001-09-07 | 2004-07-05 | 주식회사 코리아나화장품 | Stablized cosmetic material containing triple layered retonol |
JP2003267830A (en) * | 2002-03-15 | 2003-09-25 | Kose Corp | Liquid cosmetic |
JP4846989B2 (en) * | 2004-05-10 | 2011-12-28 | 株式会社コーセー | Gel cosmetic |
JP5064717B2 (en) * | 2006-04-27 | 2012-10-31 | 株式会社ファンケル | Liposomes and liposome-containing cosmetics |
JP5094041B2 (en) * | 2006-05-10 | 2012-12-12 | 旭化成ケミカルズ株式会社 | Liposomes and liposome preparations |
JP5183919B2 (en) * | 2006-12-04 | 2013-04-17 | 株式会社 資生堂 | Oil-in-water fine emulsion composition and method for producing the same |
US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
JP5508682B2 (en) * | 2007-07-27 | 2014-06-04 | 株式会社 資生堂 | Oil-in-water emulsion composition and method for producing the same |
JP2010059066A (en) * | 2008-09-02 | 2010-03-18 | Nikko Chemical Co Ltd | Alkyl glyceryl ether-mixed composition and cosmetic or skin care preparation containing the same |
WO2010143751A1 (en) * | 2009-06-12 | 2010-12-16 | 株式会社コーセー | Vesicle composition and cosmetic comprising same |
JP5657902B2 (en) * | 2010-03-17 | 2015-01-21 | 株式会社コスモステクニカルセンター | Polyoxyalkylene sterol ether derivative and / or polyoxyalkylene stanol ether derivative, and external preparation composition containing the same |
-
2011
- 2011-10-19 JP JP2012518635A patent/JP5074637B2/en active Active
- 2011-10-19 KR KR1020137003529A patent/KR101840037B1/en active IP Right Grant
- 2011-10-19 SG SG2013010277A patent/SG187808A1/en unknown
- 2011-10-19 CN CN201180041972.XA patent/CN103079529B/en active Active
- 2011-10-19 WO PCT/JP2011/073999 patent/WO2012056956A1/en active Application Filing
- 2011-10-28 TW TW100139320A patent/TWI423822B/en active
-
2013
- 2013-10-16 HK HK13111619.3A patent/HK1184065A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201225982A (en) | 2012-07-01 |
WO2012056956A1 (en) | 2012-05-03 |
JP5074637B2 (en) | 2012-11-14 |
CN103079529A (en) | 2013-05-01 |
TWI423822B (en) | 2014-01-21 |
HK1184065A1 (en) | 2014-01-17 |
CN103079529B (en) | 2016-01-06 |
KR101840037B1 (en) | 2018-03-19 |
KR20130122935A (en) | 2013-11-11 |
JPWO2012056956A1 (en) | 2014-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG187808A1 (en) | Vesicle composition, and external skin preparation and cosmetic, each containing same | |
JP6139206B2 (en) | Translucent or transparent composition | |
CN102844021B (en) | Polymer/liposome nanocomposite composition for percutaneous absorption, and method for preparing same | |
TWI451877B (en) | Emulsion composition | |
TWI618546B (en) | Emulsified composition | |
US10426715B2 (en) | Liposome composition | |
JP6778306B1 (en) | A composition for forming a lipid membrane structure and a method for producing the same, a composition containing a lipid membrane structure and a method for producing the same, a cosmetic containing the composition containing a lipid membrane structure, and an external preparation for skin. | |
CN104837479B (en) | Vesicle composition and the skin preparations for extenal use and cosmetics compounded with the vesicle composition | |
JP5109065B2 (en) | Vesicle composition and skin external preparation using the same | |
JP2016056198A (en) | Cosmetic | |
JP2010235491A (en) | Liposome for cosmetic | |
JP2016160242A (en) | Liposome dispersion liquid containing ceramides | |
JP5027601B2 (en) | Oil-in-water emulsion composition containing ascorbyl 2-phosphate magnesium salt | |
JP6411050B2 (en) | Liposomes and cosmetics containing the same | |
KR20070065945A (en) | Skin cosmetic composition | |
JP2022133154A (en) | Compositions containing lipid membrane structures and production methods thereof | |
CN102247324A (en) | Flumazenil liposome injection | |
TW201821073A (en) | Composition containing linoleic acid | |
JP5592076B2 (en) | Aqueous gel cosmetics | |
JP2014084308A (en) | Liquid crystal composition | |
JP2004538295A (en) | Composition based on lipid lamellar vesicles incorporating at least one DHEA compound | |
JP3897940B2 (en) | Lipid complex and composition for external use containing the same | |
KR20140105153A (en) | transparent gel solubilization composition containing ceramide, peptide, and hyaluronic acid | |
JP2018065762A (en) | Ursolic acid-containing liposome dispersion liquid | |
CN116940410A (en) | Liposome composition |